Eisai Refiles Mecobalamin For ALS In Japan After Seven Years

 
• By Lisa Takagi

Additional studies have shown an ultra-high dose of mecobalamin safely decreased ALS progression in early-stage patients by 43%. Japan has spent decades studying the drug’s efficacy for the disease.

If approved, mecobalamin can expand the treatment option for early ALS patients.
mecobalamin would expand ALS options in Japan if approved • Source: Shutterstock

More from Japan

More from Focus On Asia